Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Pfizer, BioNTech to co-develop potential coronavirus vaccine

share with twitter share with LinkedIn share with facebook
03/17/2020 | 01:08am EDT
A logo for Pfizer is displayed on a monitor on the floor at the NYSE in New York

U.S. drugmaker Pfizer Inc has signed a deal with Germany's BioNTech SE to co-develop a potential vaccine for the coronavirus using BioNTech's mRNA-based drug development platform, the companies said on Tuesday.

The drugmakers will start the collaboration immediately and have signed a letter of intent for the vaccine's distribution outside China, they said in a joint statement.

The companies said they will finalise financial terms, and details regarding development, manufacturing and potential commercialization of the vaccine over the next few weeks.

Reuters reported on Sunday that the German government was trying to stop the U.S. administration from persuading CureVac, another German drugmaker working on an experimental vaccine for the coronavirus, to move its research to the United States.

Pfizer and BioNTech will use research and development sites from both companies, including in the United States and Germany, the companies said.

BioNTech on Monday struck a collaboration deal with Shanghai Fosun Pharmaceutical over its rights in China to its experimental coronavirus vaccine, aiming to start testing on humans from late April.

The race is on to develop an immunisation, which is seen as by far the most effective tool to halt the global spread of the pathogen.

Rival Moderna Inc, which is working with the U.S. National Institutes of Health, on Monday announced that it dosed the first patient with its experimental coronavirus vaccine in an early-stage trial.

Pfizer already collaborates with BioNTech to develop mRNA-based vaccines for influenza.

The coronavirus outbreak has so far infected nearly 179,000 people globally and killed more than 7,000. Several countries have imposed bans on mass gatherings such as sporting, cultural and religious events to combat the disease.

(Reporting by Shubham Kalia in Bengaluru and Michael; Erman in New York; Editing by Aditya Soni)

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.55% 74.1 Delayed Quote.278.83%
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD. 5.47% 62.23 End-of-day quote.133.95%
THE GLOBAL LTD. 0.00% 183 End-of-day quote.-61.15%
share with twitter share with LinkedIn share with facebook
Latest news on SHANGHAI FOSUN PHARMACEUTI
07/30SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
07/27SHANGHAI FOSUN PHARMACEUTICAL : Says Covid-19 Vaccine in Phase 1 Clinical Trial
DJ
07/15SHANGHAI FOSUN PHARMACEUTICAL : China gives the go-ahead for human trials of Bio..
RE
07/15China gives the go-ahead for human trials of BioNTech's COVID vaccine candida..
RE
07/14SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces its Licensed COVID-19 Vac..
PU
07/12SHANGHAI FOSUN PHARMACEUTICAL : Plans to Raise $166 Million in India IPO
DJ
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
06/29Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech
RE
04/29Shanghai Fosun Pharmaceutical 1Q Net Fell 19% on Higher Research Expenses
DJ
03/30Shanghai Fosun Pharmaceutical 2019 Net Profit Rises 23%
DJ
More news
Financials
Sales 2020 32 396 M 4 647 M 4 647 M
Net income 2020 3 545 M 508 M 508 M
Net Debt 2020 13 549 M 1 943 M 1 943 M
P/E ratio 2020 44,6x
Yield 2020 0,66%
Capitalization 143 B 20 551 M 20 561 M
EV / Sales 2020 4,84x
EV / Sales 2021 4,13x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 32,91 CNY
Last Close Price 62,23 CNY
Spread / Highest target -32,5%
Spread / Average Target -47,1%
Spread / Lowest Target -65,5%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors